Phase II study of anti-TIGIT GSK4428859A (GSK’859A)/EOS-448 + anti-CD96 GSK6097608 (GSK’608) + anti-PD-1 dostarlimab in non-small cell lung cancer (NSCLC)

Jemperli (dostarlimab) - GSK

GSK6097608 - GSK

belrestotug (EOS-448) - iTeos, GSK

https://oncologypro.esmo.org/meeting-resources/esmo-congress/phase-ii-study-of-anti-tigit-gsk4428859a-gsk-859a-eos-448-anti-cd96-gsk6097608-gsk-608-anti-pd-1-dostarlimab-in-non-small-cell-lung-cancer

D.R. Spigel1; P. Garrido Lopez2; S. Cousin3; P.K. Cheema4; L.M. Rodríguez5; M.C. Garassino6; M. Kijewska7; A. Majumdar8; D.S. Theti9; S. Roy-Ghanta10; M. Ballas11; M. Reck12

Jul 28, 2022